Influence of Vertical Implant Position on Marginal Bone Loss in Cases With Thin Phenotype
The Influence of Vertical Implant Position With Immediate Temporization on Marginal Bone Loss in Cases With Thin Soft Tissue Phenotype: A Randomized Controlled Clinical Trial
Cairo University
30 participants
Jan 16, 2025
INTERVENTIONAL
Conditions
Summary
The goal of this clinical trial is to learn if vertical position of the dental implant will affect the bone around the implant in place of a missing tooth that happens to be bounded by two natural teeth. It will also measure esthetics and patient satisfaction. The main questions it aims to answer are: Does vertical implant position below the crest of the bone lead to less marginal bone loss? Will it affect implant survival as well as quality of soft tissue, esthetics and patient satisfaction? Participants will: Have an implant placed at the bone level or 2 mm below the bone level Visit the clinic once every 3 months for checkups, radiographs, and readings
Eligibility
Inclusion Criteria11
- Patients with single missing upper anterior or premolar teeth
- Patients with minimum buccolingual width of 6 mm and mesiodistal width of 6 mm
- Patients with thin soft tissue phenotype
- Patients with healthy systemic conditions.
- Patients older than 18 years.
- Good oral hygiene.
- Cooperative patients who accept a one-year follow-up period.
- Patients who consent to being part of the study (sign an informed consent form).
- Adequate inter-arch space for implant placement.
- Favorable occlusion (no traumatic occlusion).
- Absence of allergy to the prescribed medications.
Exclusion Criteria9
- Patients with inadequate bone volume and/ or quality
- Patients with local root remnants
- Patients with inadequate wound healing
- Patients with signs of acute infection related to the area of interest.
- Patients with habits that may jeopardize the implant longevity and affect the results of the study such as parafunctional habits (Lobbezoo et al., 2006).
- Heavy smokers (more than 10 cigarettes per day) (Lambert, Morris and Ochi, 2000).
- Metabolic diseases such as diabetes or hyperthyroidism as well as systemic medications such as chemotherapy or bisphosphonates
- Pregnant or nursing women.
- Uncooperative patients.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
2 mm subcrestal placement
crestal level placement
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07483086